GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For Bladder Cancer

At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options. This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29836